April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Pharmacodynamics of Dexamethasone Delivery from a Punctum Plug in Cataract Patients
Author Affiliations & Notes
  • Michael Bassett
    R&D, Ocular Therapeutix, Bedford, MA
  • Samuel Masket
    Advanced Vision Care, Los Angeles, CA
  • Thomas R Walters
    Texan Eye Care, Austin, TX
  • Michael Endl
    Fichte, Endl and Elmer Eyecare, Niagara Falls, NY
  • Jeffrey Levenson
    Levenson Eye Associates, Jacksonville, FL
  • Parag Majmudar
    Chicago Cornea Consultants, Hoffman Estates, IL
  • Deepa Mulani
    R&D, Ocular Therapeutix, Bedford, MA
  • Stephen Curwen
    R&D, Ocular Therapeutix, Bedford, MA
  • Charles D Blizzard
    R&D, Ocular Therapeutix, Bedford, MA
  • Amarpreet Sawhney
    R&D, Ocular Therapeutix, Bedford, MA
  • Footnotes
    Commercial Relationships Michael Bassett, Ocular Therapeutix (E); Samuel Masket, None; Thomas Walters, None; Michael Endl, None; Jeffrey Levenson, None; Parag Majmudar, None; Deepa Mulani, Ocular Therapeutix (E); Stephen Curwen, Ocular Therapeutix (E); Charles Blizzard, Ocular Therapeutix (E); Amarpreet Sawhney, Ocular Therapeutix (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2544. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Bassett, Samuel Masket, Thomas R Walters, Michael Endl, Jeffrey Levenson, Parag Majmudar, Deepa Mulani, Stephen Curwen, Charles D Blizzard, Amarpreet Sawhney; Pharmacodynamics of Dexamethasone Delivery from a Punctum Plug in Cataract Patients. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2544. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate the pharmacodynamic performance of dexamethasone delivered from a sustained release punctum plug (OTX-DP) when placed in the vertical canaliculus of the eye for the treatment of ocular inflammation and pain in subjects who have undergone cataract extraction with lens implantation.


OTX-DP is a punctum plug containing dexamethasone within a biodegradable PEG hydrogel matrix. The hydrogel is conjugated with fluorescein to aid plug visualization through the tissue using blue light from a slit lamp with a yellow filter. OTX-DP is designed to release dexamethasone into the tear fluid in a tapered profile over 30 days, as shown in Figure One in a preclinical beagle model. The clinical study (NCT01666210) evaluated 60 patients (30 per group) who received either OTX-DP or placebo vehicle punctum plug (PVPP) inserted into the canaliculus of the operated eye at the conclusion of cataract surgery. The PVPP is identical to OTX-DP without the drug. Over 30 days patients were monitored for ocular pain and ocular inflammation (anterior chamber cells and aqueous flare). Plug retention was assessed using a slit lamp.


Pharmacodynamic indicators in patients comparing the performance of OTX-DP to the PVPP over 30 days are presented in Table One. The OTX-DP over the study duration had more patients with an absence of cells compared to PVPP and this difference was significant at Days 14 and 30. At all time points the absence of ocular pain and anterior chamber aqueous flare was significantly lower for OTX-DP compared to PVPP. The amount of aqueous flare and cells in the anterior chamber is indicative of increased protein content and inflammatory cells and is a sign of intraocular inflammation. OTX-DP retention was 100% through 14 days and 97% at Day 30, and it was considered easy to visualize with a slit lamp.


Topical corticosteroids treat inflammation for various ophthalmic conditions including postoperative inflammation and pain. The dosing regimen requires multiple daily administrations for at least the first 2 weeks followed by tapering to a lesser frequency as the inflammation subsides. A single dose of OTX-DP at the time of surgery can be a convenient administration option to ensure treatment. Clinical results demonstrated pharmacodynamic performance as indicated in the relief of postoperative pain and reductions in key ocular inflammatory markers of cells and flare.

Keywords: 445 cataract • 487 corticosteroids • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.